BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 21507814)

  • 1. Patient factors that influence warfarin dose response.
    White PJ
    J Pharm Pract; 2010 Jun; 23(3):194-204. PubMed ID: 21507814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Warfarin therapy: evolving strategies in anticoagulation.
    Horton JD; Bushwick BM
    Am Fam Physician; 1999 Feb; 59(3):635-46. PubMed ID: 10029789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen.
    Siguret V; Gouin I; Debray M; Perret-Guillaume C; Boddaert J; Mahé I; Donval V; Seux ML; Romain-Pilotaz M; Gisselbrecht M; Verny M; Pautas E
    Am J Med; 2005 Feb; 118(2):137-42. PubMed ID: 15694897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased INR response secondary to warfarin-flucloxacillin interaction.
    Garg A; Mohammed M
    Ann Pharmacother; 2009 Jul; 43(7):1374-5. PubMed ID: 19584391
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer.
    Ruud E; Holmstrøm H; Bergan S; Wesenberg F
    Pediatr Blood Cancer; 2008 Mar; 50(3):710-3. PubMed ID: 17226852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.
    Herman D; Locatelli I; Grabnar I; Peternel P; Stegnar M; Mrhar A; Breskvar K; Dolzan V
    Pharmacogenomics J; 2005; 5(3):193-202. PubMed ID: 15824753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical factors influencing the sensitivity to warfarin when restarted after surgery.
    Schulman S; El Bouazzaoui B; Eikelboom JW; Zondag M
    J Intern Med; 2008 Apr; 263(4):412-9. PubMed ID: 18205763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal initial dose adjustment of warfarin in orthopedic patients.
    Lenzini PA; Grice GR; Milligan PE; Gatchel SK; Deych E; Eby CS; Burnett RS; Clohisy JC; Barrack RL; Gage BF
    Ann Pharmacother; 2007 Nov; 41(11):1798-804. PubMed ID: 17911206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current issues in the initial phase of warfarin therapy].
    Squizzato A; Steidl L; Ageno W
    Recenti Prog Med; 2005 Dec; 96(12):612-5. PubMed ID: 16496748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiating warfarin therapy: 5 mg versus 10 mg.
    Eckhoff CD; Didomenico RJ; Shapiro NL
    Ann Pharmacother; 2004 Dec; 38(12):2115-21. PubMed ID: 15522981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of heart failure exacerbations on anticoagulation: a prospective, observational, pilot cohort study.
    Ripley TL; Harrison D; Germany RE; Adamson PB
    Clin Ther; 2010 Mar; 32(3):506-14. PubMed ID: 20399987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching.
    Halkin H; Shapiro J; Kurnik D; Loebstein R; Shalev V; Kokia E
    Clin Pharmacol Ther; 2003 Sep; 74(3):215-21. PubMed ID: 12966365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tailoring warfarin induction doses to reflect individual and disease-specific factors.
    Ageno W; Squizzato A; Dentali F; Crowther M
    Am J Med; 2005 Feb; 118(2):143-4. PubMed ID: 15694898
    [No Abstract]   [Full Text] [Related]  

  • 14. [Use of warfarin and low range INR in the prevention of recurrent venous thrombosis].
    Quintero J; Torres E; Diez-Ewald M; Arteaga-Vizcaíno M; Vizcaíno G; León M; Rodríguez Z; Fernández N
    Invest Clin; 2011 Sep; 52(3):230-8. PubMed ID: 21950194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interaction between warfarin and oral miconazole gel].
    Ogard CG; Vestergaard H
    Ugeskr Laeger; 2000 Oct; 162(41):5511. PubMed ID: 11068529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomics and warfarin therapy.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Oct; (104):1-8. PubMed ID: 17912794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent venous thrombosis despite 'optimal anticoagulation therapy' for antiphospholipid syndrome--could new oral anticoagulants solve the problem?
    Balaban M; Stanrić V; Rincić G; Ledinsky M; Grbac L; Stancić N; Tomasić H
    Acta Clin Croat; 2010 Dec; 49(4):469-77. PubMed ID: 21830460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chitosan potentiation of warfarin effect.
    Huang SS; Sung SH; Chiang CE
    Ann Pharmacother; 2007 Nov; 41(11):1912-4. PubMed ID: 17925502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probable drug interaction between warfarin and hormonal contraceptives.
    Zingone MM; Guirguis AB; Airee A; Cobb D
    Ann Pharmacother; 2009 Dec; 43(12):2096-102. PubMed ID: 19934391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.